Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
50 HanAll's Partner HBM Announces Last Patient Dosing of Phase 1b/2a of Batoclimab in NMOSD 2021-07-19 1724
49 HanAll's Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG 2021-07-07 1703
48 HanAll Biopharma Reports First Quarter 2021 Financial Results 2021-05-06 2035
47 HanAll Biopharma Appoints David Hernandez as Vice President of Clinical Development Operations 2021-04-13 2067
46 HanAll Biopharma, Restructured to Seung-kook Park and Seung-won Jeong Joint Representative System, Accelerating Advancement as a Global Biopharmaceutical Company 2021-03-29 1663
45 HanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease 2021-03-12 1388
44 HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease 2021-02-08 1073
43 HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion 2021-01-19 1041
42 HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020 2020-11-19 1116
41 HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating Income, and Net Profit for the Third Quarter 2020-10-29 897
1 2 3 현재 페이지4 5 6 7 8